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Available online 18 October 2016A 70-year-oldmale patientwas admitted to our Cardiology Department because of shortness of breath. An intra-
venous furosemide infusion showed that volume load had been decreased. A transthoracic echocardiography
was performed after the patient was able to lie in the supine position. The ejection fraction was 25%, and there
was moderate mitral regurgitation. The end diastolic diameter was 60 mm, and a 4 × 3 cm apical thrombus
was detected. Surgical removal of the apical thrombus was not considered because of the high risk of the proce-
dure. IV thrombolytic treatmentwas suggested, but the patient rejected this approach due to the risks associated
with thrombolytic resolution of the thrombus. Warfarin treatment had not been started because the patient was
unable to come to INR (international normalized ratio) follow-up. The patient was discharged from the hospital
with a prescription, including apixaban 2 × 5mg, metoprolol 1 × 50mg, ramipril 1 × 2.5mg and spironolactone/
hydrocholorothiazide 1 × 25 mg. Complete disappearance of thrombus was observed on transthoracic echocar-
diography approximately one month later when the patient came in for polyclinic control. He had no active car-
diac symptoms, and his functional capacity was I.
© 2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Left ventricular (LV) thrombus is usually observed in dilated cardio-
myopathy (CMP) and LV aneurysms.1 Anticoagulant treatment is recom-
mended to reduce embolization risk.2 New oral anticoagulants (NOACs)
were found to be satisfactory compared to warfarin for preventing
thromboembolic disorders with non-valvular atrial ﬁbrillation.2 Never-
theless, we have very little data about apixaban treatment to resolve
LV thrombus.Case report
A 70-year-oldmale patientwith a history of smokingwas admitted to
our cardiology department due to shortness of breath. He complained
about difﬁculty breathing for two months. His functional capacity was
III. The ECG was in atrial ﬁbrillation rhythm. In his initial evaluation, the
consecutive two troponin levels were lower than the upper reference
limit. There was bilateral pleural effusion in a chest X-ray, and the cardio-
thoracic index was elevated. An intravenous (IV) furosemide infusion
showed that volume load had been decreased. Transthoracic echocardi-
ography (ECHO) was performed after the patient was able to lie in ar), drhakangunes@hotmail.com
aslan@yahoo.com (D. Akaslan),
diovascular Academy.
. Production and hosting by Elsevier Bsupine position. In his transthoracic ECHO, we detected severe global
hypokinesia with an LV ejection fraction of 25%, moderatemitral regurgi-
tation and a 4 × 3 cm thrombus in the LV. The end diastolic diameter was
60 mm (Dilated CMP) (Fig. 1). Surgical removal of the apical thrombus
was not considered because of the high risk of the procedure. IV thrombo-
lytic treatment was suggested, but the patient rejected this offer due to
the risks of thrombolytic resolution of the thrombus. Warfarin treatment
had not been initiated because the patient was unable to come to an INR
follow-up. The patient was discharged from the hospital with a prescrip-
tion including apixaban 2 × 5 mg tablet (tb), metoprolol 1 × 50 mg tb,
ramipril 1 × 2.5 mg tb and spironolactone/hydrocholorothiazide 1 ×
25 mg tb. Complete disappearance of the thrombus was observed on
transthoracic ECHO onemonth later when the patient came for polyclinic
control (Fig. 2). We performed coronary angiography on the patient be-
cause of the depressed ejection fraction. He had no ﬂow-limiting stenosis
on his coronary angiogram. He had no active cardiac symptoms, and his
functional capacity was I.Discussion
We believed this apical mass was a thrombus because the patient
had no anti-thrombotic therapy, his ECGwas in atrialﬁbrillation rhythm
and he had dilated CMP that created a tendency for thrombosis. In this
report, we treated LV thrombus with apixaban successfully. LV throm-
bus resolution with warfarin therapy was demonstrated in previous
studies.3 The role of NOACs in reducing thromboembolic risk in.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
Fig. 1. Before apixaban treatment.
Fig. 2. After apixaban treatment.
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antagonists have many limitations, such as the slow onset of action, di-
etary restrictions and a need for dose adjustments.4 NOACs do not have
these types of limitations and may also reduce the risk of hemorrhagic
stroke.4 Apixaban has been shown to have superior efﬁcacy for treating
systemic embolism, reducing stroke and all causes of mortality com-
pared to warfarin.5 We could not start warfarin with this patient be-
cause he was unable to come to an INR follow-up. Therefore, we
started apixaban 5mg2× 1 tb, and then onemonth later, the LV throm-
bus was found to be completely resolved. There are several limitations
to the use of NOACs. Careful use in elderly and patients with renal im-
pairment is recommended.6 The data are scant regarding the use of
NOACs in pregnant women, pediatric patients and patients with valvu-
lar disease.6 For apixaban, the absence of approved antidotes in the case
of life-threatening hemorrhage or surgery is another limitation for its
use.7 This case report showed that LV thrombus can be completely re-
solved by apixaban treatment. However, randomized clinical trials are
needed to elucidate and conﬁrm the use of NOACs as an alternative to
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